drugset / Trial / NCT01979406
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
RandomizedFactorialQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
Timeline
- Start
- 2013-11
- Primary completion
- 2014-10
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad4-PA-1 | Unknown | 1e+09 vg | Oral |
| Subject | Ad4-PA-1 | Unknown | 1e+10 vg | Oral |
| Subject | Ad4-PA-1 | Unknown | 1e+11 vg | Oral |
| Subject | Ad4-PA-GPI-1 | Unknown | 1e+09 vg | Oral |
| Subject | Ad4-PA-GPI-1 | Unknown | 1e+10 vg | Oral |
| Subject | Ad4-PA-GPI-1 | Unknown | 1e+11 vg | Oral |
| Subject | Anthrax vaccine adsorbed (BioThrax) | Unknown | 0.5 ml | Intramuscular |